Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Bendamustine for treatment of chronic lymphocytic leukemia.

Chang JE, Kahl BS.

Expert Opin Pharmacother. 2012 Jul;13(10):1495-505. doi: 10.1517/14656566.2012.693163. Review.

2.

Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.

Aivado M, Schulte K, Henze L, Burger J, Finke J, Haas R.

Semin Oncol. 2002 Aug;29(4 Suppl 13):19-22.

PMID:
12170428
3.

Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.

Dennie TW, Kolesar JM.

Clin Ther. 2009;31 Pt 2:2290-311. doi: 10.1016/j.clinthera.2009.11.031. Review.

PMID:
20110042
4.

Bendamustine's emerging role in the management of lymphoid malignancies.

Rummel MJ, Gregory SA.

Semin Hematol. 2011 Apr;48 Suppl 1:S24-36. doi: 10.1053/j.seminhematol.2011.03.004. Review.

PMID:
21530769
5.

Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.

Sanchez-Gonzalez B, Peñalver FJ, Medina A, Guillén H, Calleja M, Gironella M, Arranz R, Sebastian E, de Oña R, Cánovas A, de la Fuente I, Grande C, Sancho JM, Perez R, Domingo E, Lopez-Lorenzo JL, Prieto E, Panizo C, Gorosquieta A, Perez I, Cervera JM, Marin M, Mencha C, Ramila E, Salar A.

Leuk Res. 2012 Jun;36(6):709-14. doi: 10.1016/j.leukres.2011.10.024.

PMID:
22154023
6.
7.

Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.

Vidal L, Gafter-Gvili A, Gurion R, Raanani P, Dreyling M, Shpilberg O.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009045. doi: 10.1002/14651858.CD009045.pub2. Review.

PMID:
22972131
8.

Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.

Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ; German CLL Study Group..

Haematologica. 2005 Oct;90(10):1357-64.

9.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
10.

Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Elefante A, Czuczman MS.

Am J Health Syst Pharm. 2010 May 1;67(9):713-23. doi: 10.2146/ajhp090328. Review.

PMID:
20410545
11.

Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia.

Goldschmidt N, Gural A, Ben-Yehuda D, Gatt ME.

Cancer Chemother Pharmacol. 2013 Sep;72(3):709-13. doi: 10.1007/s00280-013-2243-5.

PMID:
23907444
12.

Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.

Zaja F, Mian M, Volpetti S, Visco C, Sissa C, Nichele I, Castelli M, Ambrosetti A, Puglisi S, Fanin R, Cortelazzo S, Pizzolo G, Trentin L, Rodeghiero F, Paolini R, Vivaldi P, Sancetta R, Isola M, Semenzato G.

Am J Hematol. 2013 Nov;88(11):955-60. doi: 10.1002/ajh.23546.

13.

Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.

Kath R, Blumenstengel K, Fricke HJ, Höffken K.

J Cancer Res Clin Oncol. 2001 Jan;127(1):48-54.

PMID:
11206271
14.

Bendamustine: a new look at an old drug.

Kalaycio M.

Cancer. 2009 Feb 1;115(3):473-9. doi: 10.1002/cncr.24057. Review.

15.

Bendamustine.

Keating MJ, Bach C, Yasothan U, Kirkpatrick P.

Nat Rev Drug Discov. 2008 Jun;7(6):473-4. doi: 10.1038/nrd2596. No abstract available.

PMID:
18511926
16.

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.

Montillo M, Tedeschi A, Gaidano G, Coscia M, Petrizzi VB, Orlandi E, Cascavilla N, Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, De Paoli L, Nichelatti M, Morra E, Massaia M.

Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. No abstract available.

17.

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.

Roué G, López-Guerra M, Milpied P, Pérez-Galán P, Villamor N, Montserrat E, Campo E, Colomer D.

Clin Cancer Res. 2008 Nov 1;14(21):6907-15. doi: 10.1158/1078-0432.CCR-08-0388.

18.

Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group.

Cuneo A, Marchetti M, Barosi G, Billio A, Brugiatelli M, Ciolli S, Laurenti L, Mauro FR, Molica S, Montillo M, Zinzani P, Tura S.

Leuk Res. 2014 Nov;38(11):1269-77. doi: 10.1016/j.leukres.2014.06.017.

PMID:
25063524
19.

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.

Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Merkle K, Montillo M.

Br J Haematol. 2012 Oct;159(1):67-77. doi: 10.1111/bjh.12000.

PMID:
22861163
20.

Bendamustine: a new treatment option for chronic lymphocytic leukemia.

Glode AE, Jarkowski A.

Pharmacotherapy. 2009 Nov;29(11):1375-84. doi: 10.1592/phco.29.11.1375. Review.

PMID:
19857152

Supplemental Content

Support Center